Clinical relevance of circulating cell-free microRNAs in ovarian cancer

Table 1 Circulating miRNAs as potential diagnostic biomarkers of ovarian cancer

Reference	Elevated miRNA	Decreased miRNA	Source	Tumor histology (n)		FIGO stage (n)		Control (n)
Reference	Elevated miRNA	Decreased miRNA	Source	Serous	Others	I-II	III-IV	HC	Ben	Bor
[50], 2008	miR-21, miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-205, miR-214		Serum (exosome)	50		20	30	10	10
[65], 2009	miR-21, miR92, miR-93, miR-126,miR-29a	miR-155, miR-127, miR-99b	Serum	17	11	10	18	15
[66], 2010	miR-30c-1	miR-342-3p, miR-181a, miR-450-5p	Whole blood	21	3	Relapsed		15
[67], 2012	miR-182, miR-200a, miR-200b, miR-200c		Serum	28		1	27	28
[68], 2013		miR-132, miR-26a, let7-b, miR-145	Serum	18		3	14	12
[69], 2013	miR-205	let-7f	Plasma	179	181	133	227	200
[70], 2013	miR-16, miR-21, miR-191 (EAOC) miR-16, miR-191, miR-4284 (SOC)		Plasma	21	14	12	23	20	33
[71], 2013	miR-21		Serum	68	26	32	62	40
[72], 2013	miR-221		Serum	70	26	32	64	35
[73], 2014	miR-191-5p, miR-206, miR-548a-3p, miR-320a, miR-574-3p, miR-590-5p, miR-34c-5p, miR-106b-5p	miR-19a-3p, miR-30a-5p, miR-645, miR-150-5p	Plasma	18	0	6	12	24
[74], 2014	miR-1274a, miR-625-3p, miR-720	miR-106b, miR-126, miR-150, miR-17, miR-20a, miR-92a	Plasma	42		6	36	23	36
[75], 2015	miR-7, miR-429	miR-25,miR-93	Serum	120	60	32	147	66
[41], 2015	miR-30-5p		Urine	39		16	18	30	26
[76], 2015	miR-141, miR-200c		Serum	16	58	54	20	50		19
[77], 2015		miR-145	Serum	18	64	31	63	135
[78], 2015		let-7i-5p, miR-122, miR-152, miR-25-3p	Serum/plasma	20		6	19		25
[79], 2015	miR-200a, miR-200b, miR-200c		Serum	70		33	37	70
[78], 2015	miR-200b		Plasma	51		6	45	25	25

FIGO: International Federation of Gynecology and Obstetrics, EAOC; endometriosis associated ovarian carcinoma, SOC; serous ovarian carcinoma, HC; healthy control, Ben; Benign control, Bor; borderline tumor

ISSN: 1476-4598